ANIX (Anixa Biosciences) YoY EPS Growth: 22.22% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIX Anixa Biosciences Inc ANIX
32 GF Score
Price $2.85
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences YoY EPS Growth?

Anixa Biosciences ANIX -2.41% 32 YoY EPS Growth is 22.22% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Anixa Biosciences's YoY EPS Growth for the quarter that ended in Apr. 2026 was 22.22%.

Anixa Biosciences's Earnings per Share (Diluted) for the three months ended in Apr. 2026 was $-0.07.

Anixa Biosciences YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences YoY EPS Growth Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 28.89 -21.88 12.82

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.00 30.00 0.00 20.00 22.22
ANIX
32GF Score
Anixa Biosciences Inc ANIX
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Anixa Biosciences's YoY EPS Growth for the fiscal year that ended in Oct. 2025 is calculated as:

YoY EPS Growth (A: Oct. 2025 )
=(Earnings per Share (Diluted) (A: Oct. 2025 )-Earnings per Share (Diluted) (A: Oct. 2024 ))/ | Earnings per Share (Diluted) (A: Oct. 2024 ) |
=(-0.34--0.39)/ | -0.39 |
=12.82 %

Anixa Biosciences's YoY EPS Growth for the quarter that ended in Apr. 2026 is calculated as:

YoY EPS Growth (Q: Apr. 2026 )
=(Earnings per Share (Diluted) (Q: Apr. 2026 )-Earnings per Share (Diluted) (Q: Apr. 2025 )) / | Earnings per Share (Diluted) (Q: Apr. 2025 )) |
=(-0.07--0.09)/ | -0.09 |
=22.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 22.22% mean?
Anixa Biosciences (ANIX) has a YoY EPS Growth of 22.22% as of Apr. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Anixa Biosciences and its competitors.
Is Anixa Biosciences' YoY EPS Growth too high?
Anixa Biosciences' current YoY EPS Growth is 22.22%. Overall, Anixa Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' YoY EPS Growth compare to GNLX and PMN?
Anixa Biosciences' YoY EPS Growth of 22.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Anixa Biosciences and its competitors. Anixa Biosciences's current YoY EPS Growth is 22.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current YoY EPS Growth of 22.22%. The current YoY EPS Growth is 22.22%. Anixa Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current YoY EPS Growth is 22.22% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
32GF Score

Get the complete analysis for ANIX

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.85
Price